Drug Profile
Research programme: biological therapeutics - Stealthyx Therapeutics
Alternative Names: LAP fusion proteins; Latency Associated Peptide fusion proteinsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Stealthyx
- Developer Cancer Research Technology; Stealthyx
- Class Anti-inflammatories; Antineoplastics; Interleukins; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (Parenteral)
- 30 Jun 2011 LAP-fusion protein technology is available for licensing in cancer indications as of 30 Jun 2011 (www.cancertehcnology.com)